Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($0.02), $0.19 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $20.96 million.

Guidance:

Anticipated DANYELZA® net product revenues of between $95 million and $100 million;
Anticipated operating expenses of between $115 million and $120 million;
Anticipated total annual cash burn of between $15 million and $20 million; and
Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.